BGI Group

EN Texte en anglais Pas encore d'article dans ta langue : extrait en anglais.

BGI Group, formerly Beijing Genomics Institute, is a Chinese genomics company with headquarters in Yantian, Shenzhen. The company was originally formed in 1999 as a genetics research center to participate in the Human Genome Project. It also sequences the genomes of other animals, plants and microorganisms. BGI has transformed from a small research institute, notable for decoding the DNA of pandas and rice plants, into a diversified company active in animal cloning, health testing, and contract research. BGI's earlier research was continued by the Beijing Institute of Genomics, Chinese Academy of Sciences. BGI Research, the group's nonprofit division, works with the Institute of Genomics and operates the China National GeneBank under a contract with the Chinese government. BGI Genomics, a subsidiary, was listed on the Shenzhen Stock Exchange in 2017. The company is supported by several China Government Guidance Funds and Chinese state-owned enterprises. Starting in 2021, details came to light about multiple controversies involving the BGI Group. These controversies include alleged collaboration with the People's Liberation Army (PLA) and use of genetic data from prenatal tests. BGI denied that it shares prenatal genetics data with the PLA.